Modality
Small Molecule
MOA
C5i
Target
IL-17A
Pathway
Checkpoint
Wet AMD
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
Sep 2018
→ Jul 2030
Phase 2Current
NCT07257599
2,715 pts·Wet AMD
2018-09→2030-07·Not yet recruiting
2,715 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-074.3y awayPh2 Data· Wet AMD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2030-07-07 · 4.3y away
Wet AMD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07257599 | Phase 2 | Wet AMD | Not yet recr... | 2715 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C |